Literature DB >> 18762460

Activation of Rho-kinase in the brainstem enhances sympathetic drive in mice with heart failure.

Koji Ito1, Yoshikuni Kimura, Yoshitaka Hirooka, Yoji Sagara, Kenji Sunagawa.   

Abstract

Rho-kinase is involved in the pathogenesis of hypertension and left ventricular remodelling after myocardial infarction (MI). In an earlier study, we had demonstrated that Rho-kinase in the brainstem contributes to hypertensive mechanisms via the sympathetic nervous system; however, it is not known whether Rho-kinase in the brainstem also contributes to sympathetic nerve activation after MI. Male Institute of Cancer Research mice (8-10 weeks old) were used for the study. Two days before coronary artery occlusion (MI group), the left ventricular function was estimated by echocardiography. Following this, Y-27632 (0.5 mM, 0.25 microL/h), a specific Rho-kinase inhibitor, or a vehicle was intracisternally infused in the mice using an osmotic mini-pump. Nine days after coronary artery occlusion, we evaluated the 24-hour urinary norepinephrine excretion (U-NE) as a marker of sympathetic nerve activity. Ten days after coronary artery occlusion, we measured organ weight and evaluated Rho-kinase activity in the brainstem by measuring the amount of phosphorylated ezrin/radixin/moesin proteins, one of the substrates of Rho-kinase. The control group underwent a sham operation. Rho-kinase activity, U-NE, and lungs and liver weight were significantly greater in the MI group compared with the control group. Left ventricular size increased and percent fractional shortening decreased in the MI group compared with the control group. Y-27632 significantly decreased Rho-kinase activity and attenuated the increase in U-NE after MI. These results demonstrate that Rho-kinase is activated in the brainstem after MI and that the activation of this pathway is involved in the resulting enhanced sympathetic drive.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18762460     DOI: 10.1016/j.autneu.2008.07.010

Source DB:  PubMed          Journal:  Auton Neurosci        ISSN: 1566-0702            Impact factor:   3.145


  7 in total

Review 1.  Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.

Authors:  Jianjian Shi; Lei Wei
Journal:  J Cardiovasc Pharmacol       Date:  2013-10       Impact factor: 3.105

Review 2.  Rho kinase as a therapeutic target in cardiovascular disease.

Authors:  Michelle Surma; Lei Wei; Jianjian Shi
Journal:  Future Cardiol       Date:  2011-09

3.  Silencing nox4 in the paraventricular nucleus improves myocardial infarction-induced cardiac dysfunction by attenuating sympathoexcitation and periinfarct apoptosis.

Authors:  David W Infanger; Xian Cao; Scott D Butler; Melissa A Burmeister; Yi Zhou; John A Stupinski; Ram V Sharma; Robin L Davisson
Journal:  Circ Res       Date:  2010-04-22       Impact factor: 17.367

4.  Central Rho kinase inhibition restores baroreflex sensitivity and angiotensin II type 1 receptor protein imbalance in conscious rabbits with chronic heart failure.

Authors:  Karla K V Haack; Lie Gao; Alicia M Schiller; Pamela L Curry; Peter R Pellegrino; Irving H Zucker
Journal:  Hypertension       Date:  2013-01-02       Impact factor: 10.190

5.  Central Angiotensin-II Increases Blood Pressure and Sympathetic Outflow via Rho Kinase Activation in Conscious Rabbits.

Authors:  Peter R Pellegrino; Alicia M Schiller; Karla K V Haack; Irving H Zucker
Journal:  Hypertension       Date:  2016-09-26       Impact factor: 10.190

6.  Early postnatal low-protein nutrition, metabolic programming and the autonomic nervous system in adult life.

Authors:  Júlio Cezar de Oliveira; Sabrina Grassiolli; Clarice Gravena; Paulo Cezar Freitas de Mathias
Journal:  Nutr Metab (Lond)       Date:  2012-09-11       Impact factor: 4.169

7.  Central mechanisms of abnormal sympathoexcitation in chronic heart failure.

Authors:  Takuya Kishi; Yoshitaka Hirooka
Journal:  Cardiol Res Pract       Date:  2012-08-07       Impact factor: 1.866

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.